What is the 13F Pro Quality Score for TEVA?

13F Pro ranks TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TEVA's current score at https://13fpro.ai/company/TEVA (free sign-up required for the full ranking).

Where does 13F Pro source TEVA data?

All TEVA PHARMACEUTICAL INDUSTRIES LTD fundamentals and ownership data come directly from SEC EDGAR. TEVA PHARMACEUTICAL INDUSTRIES LTD files with the SEC under CIK 818686. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TEVA in?

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TEVA research updated on 13F Pro?

TEVA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TEVA PHARMACEUTICAL INDUSTRIES LTD(TEVA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 818686 TEVA stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

56.7/100

Rank #1,138 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TEVA Scores 57/100

exact factor attribution · 2026-09-11

TEVA's composite is driven by scale and earnings quality, held back by revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+5.8 pts

89th pct

Earnings quality

+3.8 pts

88th pct

Profitability

+1.9 pts

62th pct

Institutional flow

+1.6 pts

81th pct

Free cash flow

+0.6 pts

54th pct

Shareholder dilution

+0.3 pts

57th pct

Earnings growth

+0.1 pts

53th pct

Capital efficiency

-0.0 pts

50th pct

Revenue growth

-7.4 pts

13th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TEVA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TEVA at 56.7/100 on a 32-signal composite quality model, placing it at rank #1,138 of 2,962 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), TEVA PHARMACEUTICAL INDUSTRIES LTD reports quarterly revenue of $4.1B, net income of $-576.0M, free cash flow of $307.0M. Top institutional holders of TEVA by reported 13-F value include BlackRock, Harel Insurance Investments & Financial Services Ltd., Phoenix Financial Ltd., based on the most recent SEC filings. TEVA trades on the NYSE exchange and files with the SEC under CIK 818686. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TEVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TEVA PHARMACEUTICAL INDUSTRIES LTD directly from SEC EDGAR. TEVA PHARMACEUTICAL INDUSTRIES LTD's 13F Pro composite quality score has ranged between 51 and 57 since 2026, currently 56.7 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

Revenue

Q2 2026

$4.1B

Net Income

Q2 2026

$-576.0M

Free Cash Flow

Q2 2026

$307.0M

ROIC

Q2 2026

-5.5%

D/E Ratio

Q2 2026

1.16

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.3% YoY

$17.26BFY 2025

FY22 $14.93BFY23 $15.85BFY24 $16.54BFY25 $17.26B

Net Income

+186.0% YoY

$1.41BFY 2025

FY22 $-2.45BFY23 $-559.0MFY24 $-1.64BFY25 $1.41B

Operating Income

+811.9% YoY

$2.16BFY 2025

FY22 $-2.20BFY23 $433.0MFY24 $-303.0MFY25 $2.16B

EPS (Diluted)

+183.4% YoY

$1.21FY 2025

FY22 $-2.20FY23 $-0.50FY24 $-1.45FY25 $1.21

Total Assets

+3.6% YoY

$40.75BFY 2025

FY22 $44.01BFY23 $43.48BFY24 $39.33BFY25 $40.75B

Total Debt

+2.2% YoY

$3.62BFY 2025

FY22 $4.20BFY23 $3.32BFY24 $3.54BFY25 $3.62B

Op. Cash Flow

+32.2% YoY

$1.65BFY 2025

FY22 $1.59BFY23 $1.37BFY24 $1.25BFY25 $1.65B

Free Cash Flow

+53.3% YoY

$1.15BFY 2025

FY22 $1.04BFY23 $842.0MFY24 $749.0MFY25 $1.15B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$17.26B +4.3%	$16.54B +4.4%	$15.85B +6.2%	$14.93B -6.0%	$15.88B -4.7%	$16.66B
Net Income	$1.41B +186.0%	$-1.64B -193.2%	$-559.0M +77.1%	$-2.45B -686.6%	$417.0M +110.5%	$-3.99B
Operating Income	$2.16B +811.9%	$-303.0M -170.0%	$433.0M +119.7%	$-2.20B -228.0%	$1.72B +148.0%	$-3.57B
EPS (Diluted)	$1.21 +183.4%	$-1.45 -190.0%	$-0.50 +77.3%	$-2.20 -678.9%	$0.38 +110.4%	$-3.64
Total Assets	$40.75B +3.6%	$39.33B -9.6%	$43.48B -1.2%	$44.01B -7.7%	$47.67B -5.9%	$50.64B
Total Debt	$3.62B +2.2%	$3.54B +6.6%	$3.32B -20.8%	$4.20B +48.3%	$2.83B -51.7%	$5.86B
Operating Cash Flow	$1.65B +32.2%	$1.25B -8.8%	$1.37B -14.0%	$1.59B +99.2%	$798.0M -34.4%	$1.22B
Free Cash Flow	$1.15B +53.3%	$749.0M -11.0%	$842.0M -19.2%	$1.04B +341.5%	$236.0M -63.0%	$638.0M

Get alerted when TEVA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TEVA PHARMACEUTICAL INDUSTRIES LTD including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TEVA

BlackRock, Inc.
$2.2B63,894,301 sh
Harel Insurance Investments & Financial Services Ltd.
$1.6B48,138,805 sh
Phoenix Financial Ltd.
$1.5B42,933,367 sh
WCM INVESTMENT MANAGEMENT, LLC
$1.4B41,315,232 sh
Clal Insurance Enterprises Holdings Ltd
$1.4B40,596,506 sh
MENORA MIVTACHIM HOLDINGS LTD.
$1.4B39,854,383 sh
Migdal Insurance & Financial Holdings Ltd.
$1.3B38,922,212 sh
NORGES BANK
$1.1B32,299,753 sh
FMR LLC
$1.0B30,258,016 sh
Lingotto Investment Management LLP
$684.6M20,205,943 sh

Fund	Value	Shares
BlackRock, Inc.	$2.2B	63,894,301
Harel Insurance Investments & Financial Services Ltd.	$1.6B	48,138,805
Phoenix Financial Ltd.	$1.5B	42,933,367
WCM INVESTMENT MANAGEMENT, LLC	$1.4B	41,315,232
Clal Insurance Enterprises Holdings Ltd	$1.4B	40,596,506
MENORA MIVTACHIM HOLDINGS LTD.	$1.4B	39,854,383
Migdal Insurance & Financial Holdings Ltd.	$1.3B	38,922,212
NORGES BANK	$1.1B	32,299,753
FMR LLC	$1.0B	30,258,016
Lingotto Investment Management LLP	$684.6M	20,205,943

Companies Similar to TEVA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VTRS

Viatris Inc

AI score

Similar quality profile · 12 shared holders

Rubric Capital Management LP GLENVIEW CAPITAL MANAGEMENT, LLC DME Capital Management, LP

GEHC

GE HealthCare Technologies Inc.

AI score

Similar quality profile · 19 shared holders

SOUND SHORE MANAGEMENT INC /CT/MENORA MIVTACHIM HOLDINGS LTD.National Pension Service

ZBH

ZIMMER BIOMET HOLDINGS, INC.

AI score

Similar quality profile · 17 shared holders

Capital International Investors SOUND SHORE MANAGEMENT INC /CT/National Pension Service

BIIB

BIOGEN INC.

AI score

Similar quality profile · 21 shared holders

Alyeska Investment Group, L.P.AustralianSuper Pty Ltd National Pension Service

BDX

BECTON DICKINSON & CO

AI score

Similar quality profile · 12 shared holders

National Pension Service AVIVA PLC Korea Investment CORP

BMY

BRISTOL MYERS SQUIBB CO

AI score

Similar quality profile · 18 shared holders

Capital World Investors Capital International Investors AustralianSuper Pty Ltd

OGN

Organon & Co.

AI score

Similar quality profile · 2 shared holders

PRIVATE MANAGEMENT GROUP INC ADAR1 Capital Management, LLC

PFE

PFIZER INC

AI score

Similar quality profile · 19 shared holders

Capital World Investors SOUND SHORE MANAGEMENT INC /CT/National Pension Service

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TEVA on your watchlist

Track score changes the day TEVA PHARMACEUTICAL INDUSTRIES LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TEVA a good stock to buy?

13F Pro's AI-powered analysis of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TEVA are available on the TEVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TEVA is classified as a large company.

Which hedge funds own TEVA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TEVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TEVA PHARMACEUTICAL INDUSTRIES LTD's investment landscape.